Lithium hydroxide, monohydrate → HCID 18444021, compound
Reaction equation
[Cl:1][C:2]1[CH:7]=[CH:6][CH:5]=[C:4]([Cl:8])[C:3]=1[CH:9]1[O:13][C:12](=[O:14])[CH:11]([CH2:15][C:16]2[CH:21]=[CH:20][C:19]([N:22]3[C:31](=[O:32])[C:30]4[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=4)[N:24]([CH3:33])[C:23]3=[O:34])=[CH:18][CH:17]=2)[CH2:10]1.[OH2:35].[OH-].[Li+]>O1CCCC1>[Cl:1][C:2]1[CH:7]=[CH:6][CH:5]=[C:4]([Cl:8])[C:3]=1[CH:9]([OH:13])[CH2:10][CH:11]([CH2:15][C:16]1[CH:21]=[CH:20][C:19]([N:22]2[C:31](=[O:32])[C:30]3[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=3)[N:24]([CH3:33])[C:23]2=[O:34])=[CH:18][CH:17]=1)[C:12]([OH:35])=[O:14]Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
The mixture of 7 mg of 3-[4-[[5-(2,6-dichlorophenyl)-2-oxotetrahydrofuran-3-yl]methyl]phenyl]-1-methylquinazoline-2,4-dione, 0.6 mg of lithium hydroxide-monohydrate and 5 ml of tetrahydrofuran was stirred. After removing a solvent, the residue was purified by reverse phase HPLC to obtain the subject compound.
Workup
- customAfter removing a solvent
- customthe residue was purified by reverse phase HPLC
- customto obtain the subject compound
Sources & evidence
- ORD record
- ord-5619e57f2cee4a6195df74ed3901857b
- Source dataset
- uspto-grants-2007_03
- Patent number
- US07193108B2
Reaction notes
Loading…